← All Kairos Pharma, LTD filings

Kairos Pharma, LTD DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

AMEX
KAPA
Kairos Pharma, LTD
DEF: Kairos Pharma 2026 Annual Meeting Proxy Statement
Kairos Pharma has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, a reverse stock split, and equity plan amendments.
AMEX
KAPA
Kairos Pharma, LTD
DEFR14A: Kairos Pharma Seeks Stockholder Approval for Equity Line of Credit Agreement at Upcoming Annual Meeting
Kairos Pharma is seeking stockholder approval for several key proposals at its upcoming annual meeting, including the election of directors, ratification of auditors, and approval of an equity line of credit agreement.
AMEX
KAPA
Kairos Pharma, LTD
DEF 14A: Kairos Pharma Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Kairos Pharma announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory votes.
AMEX
KAPA
Kairos Pharma, LTD
DEF 14C: Kairos Pharma Secures Stockholder Approval for Share Issuance to Fund Clinical Trials
Kairos Pharma obtained majority stockholder approval to issue shares exceeding 19.99% of outstanding common stock to facilitate funding for clinical trials and general corporate purposes.